Litigation Details for Cubist Pharmaceuticals LLC v. Sagent Pharmaceuticals, Inc. (D. Del. 2015)

Cubist Pharmaceuticals LLC v. Sagent Pharmaceuticals, Inc. (D. Del. 2015)

Docket		Date Filed	2015-12-17
Court	District Court, D. Delaware	Date Terminated	2016-03-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,468,967; 6,852,689; 8,058,238; 8,129,342
Link to Docket	External link to docket

Details for Cubist Pharmaceuticals LLC v. Sagent Pharmaceuticals, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-12-17				External link to document
2015-12-16	1		FDA. 10. United States Patent No. 6,468,967 (“the ’967 patent”), entitled “Methods for Administration…CUBICIN® prior to the expiration of U.S. Patent Nos. 6,468,967; 6,852,689; 8,058,238; and 8,129,342. … Infringement of U.S. Patent No. 6,468,967 23. Plaintiff incorporates … 1. This is an action for patent infringement under the patent laws of the United States, Title…2019. 11. United States Patent No. 6,852,689 (“the ’689 patent”), entitled “Methods for Administration	External link to document
2015-12-16	3		/9/15. Date of Expiration of Patent: The 6,468,967 and 6,852,689 patents expire on September 24, 2019.… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2019. The 8,058,238 and 8,129,342 patents expire on November 18, 2020..Thirty Month Stay Deadline: 5/9/2018…2015 2 March 2016 1:15-cv-01164 830 Patent None District Court, D. Delaware	External link to document

Cubist Pharmaceuticals LLC v. Sagent Pharmaceuticals Inc. Litigation Summary, 1:15-cv-01164

Last updated: August 2, 2026

Cubist Pharmaceuticals LLC sued Sagent Pharmaceuticals Inc. in the U.S. District Court for the District of Delaware after Sagent filed an abbreviated new drug application seeking approval to market generic daptomycin for injection, the active ingredient in Cubist’s CUBICIN product. The case was a Hatch-Waxman patent infringement action under 35 U.S.C. § 271(e)(2).

The litigation involved CUBICIN patent rights, not biologic exclusivity or biosimilar regulation. The case ended without a publicly reported trial decision or merits judgment. The docket reflects termination through a stipulated dismissal, consistent with a confidential settlement. The public record does not establish the settlement’s launch date, payment terms, or licensing conditions. [1]

What drug and product were at issue in Cubist v. Sagent?

The dispute concerned daptomycin for injection, an intravenous lipopeptide antibacterial used primarily for complicated skin and skin-structure infections and bloodstream infections caused by susceptible Gram-positive organisms.

Item	Detail
Brand product	CUBICIN
Active ingredient	Daptomycin
Dosage form	Sterile lyophilized powder for intravenous injection
Reference sponsor	Cubist Pharmaceuticals LLC
Later parent company	Merck & Co., Inc.
Generic applicant	Sagent Pharmaceuticals Inc.
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:15-cv-01164
Judge	Richard G. Andrews
Case type	Paragraph IV patent litigation

Cubist commercialized CUBICIN before Merck acquired Cubist in 2015. Merck became the principal commercial owner of the CUBICIN franchise during the litigation period.

What patents protected CUBICIN in the Sagent litigation?

The case was based on Cubist’s Orange Book-listed daptomycin patents identified in the complaint and related patent records. The principal patent issues involved the scope and remaining term of CUBICIN patent protection rather than the validity of the original daptomycin molecule patent.

The relevant CUBICIN patent estate included patents directed to daptomycin products, formulations, dosing, and methods of treatment. Patent scope and listing status varied by product presentation and by the Orange Book edition applicable at the time of Sagent’s ANDA certification.

What were the principal CUBICIN patents?

The public case record identifies the following patents as central to the CUBICIN patent dispute:

Patent	General subject matter	Litigation relevance
U.S. Patent No. 6,468,967	Daptomycin-related pharmaceutical protection	Core CUBICIN patent rights asserted against generic entry
U.S. Patent No. 7,456,168	Daptomycin pharmaceutical and treatment protection	Additional patent barrier identified in the CUBICIN portfolio

The exact asserted claims, infringement theories, and defenses must be read from the complaint, Sagent’s notice of Paragraph IV certification, and the operative pleadings. Patent titles alone do not establish which claims were ultimately litigated or resolved by settlement.

What did Sagent’s Paragraph IV challenge mean?

Sagent’s ANDA filing triggered a Paragraph IV dispute under the Hatch-Waxman Act. A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Filing the ANDA with that certification created an artificial act of infringement under 35 U.S.C. § 271(e)(2), allowing Cubist to sue before commercial launch.

The filing also triggered the statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions. During the stay, FDA generally could not give final approval to the ANDA unless the litigation ended earlier, the court ordered otherwise, or the stay expired.

What defenses did Sagent likely present?

The available public materials identify the case as a Paragraph IV action, but the docket does not provide a public merits ruling resolving every defense. The standard defenses in this type of daptomycin litigation included:

• Noninfringement of the asserted formulation or method claims.
• Invalidity for anticipation.
• Invalidity for obviousness under 35 U.S.C. § 103.
• Lack of written description or enablement under 35 U.S.C. § 112.
• Unenforceability based on inequitable conduct, if pleaded.
• Challenges to the scope or enforceability of Orange Book-listed rights.

Because the case ended through dismissal rather than a reported trial judgment, there is no judicial holding in this docket establishing that the asserted CUBICIN patents were valid, infringed, or enforceable.

When did Cubist v. Sagent begin and end?

The case was filed in the District of Delaware in 2015. The action was later terminated through a stipulated dismissal after the parties reached a settlement.

Event	Timing
Cubist filed the complaint	2015
Sagent defended against the Paragraph IV allegations	During the 2015-2016 litigation period
Settlement or resolution	Before final trial judgment
Case disposition	Stipulated dismissal
Public merits ruling	None reported
Public settlement terms	Not disclosed

The dismissal means the docket does not provide a court-determined patent expiration or launch date for Sagent’s generic. Any commercial entry right would have depended on the confidential settlement, FDA approval, manufacturing readiness, and other regulatory conditions.

What was the litigation status and final outcome?

The publicly available litigation record supports four conclusions:

1. Cubist asserted CUBICIN patent rights against Sagent’s ANDA.
2. Sagent’s filing was a Paragraph IV challenge.
3. The parties resolved the dispute without a publicly reported trial or final validity decision.
4. The case was dismissed by stipulation rather than adjudicated on the merits.

The settlement likely removed the immediate litigation barrier between the parties, but the public docket does not disclose whether Sagent received an agreed launch date, a license, a supply arrangement, or another form of market access. A stipulated dismissal alone does not establish that Sagent launched, that FDA granted final approval, or that Sagent obtained an exclusive license.

Did the case create a legal precedent for CUBICIN patent validity?

No. Cubist v. Sagent did not produce a reported claim-construction opinion, summary-judgment decision, trial verdict, or appellate ruling that would establish binding precedent on CUBICIN patent validity or infringement.

The case therefore had limited precedential value. Its commercial importance arose from the potential generic entry risk against a major hospital antibacterial franchise and from the settlement’s ability to resolve Sagent’s specific ANDA challenge.

The absence of a merits decision leaves several legal questions unresolved in this docket:

• Whether the asserted claims would have survived an obviousness challenge.
• Whether Sagent’s proposed product would have infringed formulation claims.
• Whether any treatment-method claims were enforceable against the ANDA product.
• Whether the patents were valid for their full listed terms.
• Whether the patents would have supported an injunction against commercial launch.

What was the Orange Book status of CUBICIN?

CUBICIN was listed in the FDA Orange Book as a prescription antibacterial product with associated patent information. Orange Book listings provide notice to generic applicants and form the basis for Paragraph IV certifications, but they do not establish that a listed patent is valid or enforceable.

The Orange Book distinguishes between:

• Drug-substance patents.
• Drug-product or formulation patents.
• Method-of-use patents.
• Patents associated with particular dosage forms or presentations.

For CUBICIN, the relevant patent estate included product and treatment-related protection. The listing status could change as patents expired, pediatric exclusivity periods ended, or FDA accepted new patent information for related presentations such as CUBICIN RF.

A generic applicant may challenge listed patents even when the reference product has multiple patents. FDA approval depends on the ANDA applicant’s certifications and the statutory stay, while infringement and validity are determined by the courts.

What formulation patents protected daptomycin?

Daptomycin is a complex lipopeptide that requires a stable injectable formulation and controlled reconstitution. Formulation patents can protect matters such as:

• The composition of the sterile powder.
• Excipients and stabilizers.
• Manufacturing and lyophilization parameters.
• Reconstitution characteristics.
• Storage stability.
• Container and presentation configurations.
• Compatibility with infusion solutions.

Formulation patents can be commercially significant even after broad compound protection has expired. They may require a generic applicant to design around specific excipient ratios, manufacturing conditions, or product characteristics. The applicant can also certify that the proposed product does not infringe, or challenge the patent’s validity.

For CUBICIN, the formulation question was distinct from whether daptomycin itself remained patent-protected. A generic product could avoid a formulation claim while still being therapeutically substitutable, provided it complied with FDA requirements and did not infringe other valid claims.

What method-of-use patents affected generic daptomycin entry?

Method-of-use patents can cover the use of daptomycin for particular infections, patient populations, dosing schedules, or treatment durations. In an ANDA proceeding, an applicant may use a Section viii statement to carve out a patented indication from its proposed labeling when the remaining label does not practice the patented method.

This creates a regulatory and litigation distinction:

• A product patent can block approval or commercial marketing of the drug product itself.
• A method-of-use patent may be addressed through a label carve-out.
• A generic may obtain approval for non-patented indications while the branded sponsor retains protection for a patented use.

The public record for Cubist v. Sagent does not provide a final judicial determination that any particular CUBICIN method-of-use claim was infringed. The settlement prevented that issue from producing a binding decision.

How strong was the CUBICIN patent estate?

The estate was commercially meaningful but became weaker as the core patent terms approached expiration and generic applicants developed alternative infringement positions.

Strengths

• CUBICIN was an approved injectable product with a defined FDA reference listing.
• Cubist had multiple patent categories, including product, formulation, and use-related rights.
• The Delaware action created the possibility of a 30-month stay.
• Daptomycin’s injectable formulation and manufacturing requirements could create technical barriers beyond patent expiration.
• Hospital procurement and antimicrobial contracting could delay rapid generic substitution even after approval.

Weaknesses

• The original daptomycin discovery rights were older than the CUBICIN commercial franchise.
• Later patents generally provided narrower protection than a broad compound patent.
• Generic applicants could challenge patent validity under Paragraph IV.
• Method-of-use protection can sometimes be addressed through labeling restrictions.
• A settlement without a merits ruling leaves the portfolio’s litigation resilience untested.

The estate’s practical strength therefore depended on the asserted claims, remaining patent term, the technical design of Sagent’s product, and the commercial value of delaying entry.

What generic entry risks existed for CUBICIN?

The principal risk was an FDA-approved generic daptomycin product entering the U.S. market before full exhaustion of all commercially relevant CUBICIN rights.

Immediate risk

Sagent’s Paragraph IV filing created litigation risk and the possibility of an agreed or court-determined launch date. The 30-month stay delayed FDA approval but did not permanently prevent entry.

Post-settlement risk

After dismissal, Sagent could potentially proceed under settlement terms. The public record does not show whether the agreement permitted:

• Entry before patent expiration.
• Entry on a specified future date.
• Entry upon invalidation or expiration of particular patents.
• Authorized-generic distribution.
• A license limited to certain indications or formulations.

Market risk

Daptomycin generic entry could affect:

• CUBICIN net sales.
• Hospital contracting leverage.
• Intravenous antibiotic pricing.
• Formulary positioning.
• Merck’s revenue expectations for the franchise.
• Manufacturing utilization at branded and generic facilities.

The impact would likely depend on the number of approved competitors, supply reliability, hospital purchasing contracts, and whether substitution was automatic under state pharmacy law.

Did the case involve biosimilar risk?

No. Daptomycin is a small-molecule active pharmaceutical ingredient regulated through the ANDA pathway. Cubist v. Sagent was not a biosimilar case under the Public Health Service Act.

The relevant competitive risks were:

• ANDA generic entry.
• Paragraph IV patent challenges.
• Formulation design-arounds.
• Potential authorized-generic competition.
• Hospital purchasing substitution.

Biosimilar concepts such as reference-product exclusivity under the Biologics Price Competition and Innovation Act do not apply to this case.

Which companies challenged or competed against CUBICIN?

Sagent was one of the generic applicants involved in the CUBICIN patent litigation landscape. Other generic manufacturers pursued or commercialized daptomycin products through separate regulatory and patent pathways.

The broader competitive group included companies active in injectable anti-infectives, such as:

• Fresenius Kabi.
• Hospira, later part of Pfizer.
• Teva Pharmaceuticals.
• Dr. Reddy’s Laboratories.
• Other ANDA sponsors depending on FDA approval timing and product availability.

Separate litigation involving other applicants cannot be treated as part of the Sagent case. Each applicant’s ANDA, Paragraph IV certification, product design, settlement, and launch terms required separate analysis.

What licensing deals or settlement agreements affected Sagent?

The parties resolved the action without publicly disclosing the material business terms. The public dismissal does not identify:

• A royalty rate.
• A launch date.
• A license grant.
• A supply agreement.
• An authorized-generic arrangement.
• A payment by either party.
• Restrictions on indications or distribution channels.

The settlement should therefore be classified as commercially material but publicly opaque. It resolved the litigation risk between Cubist and Sagent without clarifying the underlying patent merits.

What are the geographic coverage and manufacturing barriers?

The lawsuit was a U.S. District of Delaware action and concerned U.S. patent rights and an FDA-regulated ANDA. It did not determine patent rights in Europe, Canada, Japan, or other jurisdictions.

Geographic risk depended on separate national patent families, regulatory approvals, and local launch rights. A U.S. settlement would not automatically grant Sagent freedom to market daptomycin outside the United States.

Manufacturing and technical barriers included:

• Sterile injectable production.
• Lyophilization capacity.
• Control of daptomycin purity and potency.
• Reconstitution performance.
• Stability during storage.
• Container-closure integrity.
• FDA inspection and approval requirements.
• Reliable supply of a complex antibacterial product.

These barriers could delay entry even after patent litigation ended. They did not, however, substitute for patent protection and did not extend patent terms.

How does Cubist v. Sagent compare with a typical ANDA patent case?

Issue	Cubist v. Sagent	Typical ANDA case
Product	Injectable small-molecule antibacterial	Small molecule or other FDA-approved drug
Legal pathway	Paragraph IV	Paragraph IV
Patent dispute	CUBICIN product, formulation, and use rights	Listed patents for the reference drug
Court outcome	Settlement and stipulated dismissal	Trial, settlement, or dismissal
Precedent	No reported merits ruling	Depends on case
Biosimilar issues	None	None in a conventional ANDA case
Commercial concern	Generic hospital injectable entry	Substitution and price erosion
Public settlement terms	Not disclosed	Often confidential

Key Takeaways

• Cubist sued Sagent over an ANDA for generic daptomycin for injection.
• The case was a Hatch-Waxman Paragraph IV action in the District of Delaware.
• The dispute concerned CUBICIN patent rights, including patents associated with daptomycin products and treatments.
• The case ended through stipulated dismissal after settlement.
• No reported court decision established the validity, enforceability, or infringement of the asserted patents.
• Public records do not disclose Sagent’s launch date, royalty obligations, license terms, or commercial restrictions.
• The case involved generic, not biosimilar, competition.
• CUBICIN’s commercial exposure depended on patent term, FDA approval, hospital contracting, manufacturing capacity, and the number of competing injectable daptomycin suppliers.

FAQs About Cubist Pharmaceuticals LLC v. Sagent Pharmaceuticals Inc.

Was Sagent authorized to launch generic daptomycin after the settlement?

The public docket does not disclose the settlement’s launch provisions. Stipulated dismissal alone does not establish the date or conditions of Sagent’s market entry.

Did Cubist win the patent case against Sagent?

No merits victory was entered. The case ended by settlement and dismissal rather than a trial judgment.

Was CUBICIN protected by a biologic exclusivity period?

No. CUBICIN is a small-molecule antibacterial product regulated through the ANDA pathway.

Could Sagent avoid CUBICIN method-of-use patents through a label carve-out?

Potentially. Hatch-Waxman Section viii procedures can allow a generic applicant to omit patented indications, but the feasibility depends on the listed use, proposed label, and infringement analysis.

Did the Sagent litigation invalidate any CUBICIN patent?

No. The docket does not report an invalidity judgment in favor of Sagent.

References

1. U.S. District Court for the District of Delaware. (2015-2016). Cubist Pharmaceuticals LLC v. Sagent Pharmaceuticals, Inc., No. 1:15-cv-01164-RGA, docket filings and stipulated dismissal.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Food and Drug Administration. (n.d.). CUBICIN (daptomycin for injection) prescribing information. FDA.

4. Hatch-Waxman Amendments, 21 U.S.C. § 355(j).

5. Patent Act, 35 U.S.C. § 271(e)(2).